• Home
  • MSN Laboratories
6-8
Oct
2026
CPHI Milan 2026
Fiera Milano, Italy
7A34
Book a meeting
23-25
Nov
2026
CPHI India 2026
IICC, Yashobhoomi, Dwarka, Delhi
1D16
Book a meeting
14-16
Dec
2026
CPHI Middle East 2026
Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia
H1.V90
Book a meeting

MSN Laboratories

About MSN Laboratories

MSN Laboratories was founded in 2003 and is one of the fastest growing pharmaceutical manufacturers of APIs and finished dosages in India. We have Nine API and Five Finished dosage facilities & an integrated R&D Center located in Hyderabad.

Our state-of-the-art facilities are accredited by  USFDA, EU:GMP, WHO:Geneva, PIC/S, ANVISA, Invima and many other global approvals. With a product portfolio covering 35 major therapies including Oncology, MSN reaches out to millions of people in 65 countries across North America, Europe, Latin America, CIS, Middle East, Africa & Asia.  

Our strengths are our world-class facilities, innovation driven R&D, strong IPM,...

Read more Show less
Sales Markets
Show more Show less
Categories
more categories Show less

Meet us at

  • CPHI Milan 2026

    CPHI Milan 2026

    Fiera Milano, Italy
    6 Oct 2026 - 8 Oct 2026
  • CPHI India 2026

    CPHI India 2026

    IICC, Yashobhoomi, Dwarka, Delhi
    23 Nov 2026 - 25 Nov 2026
  • CPHI Middle East 2026

    CPHI Middle East 2026

    Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia
    14 Dec 2026 - 16 Dec 2026
  • Country/Region:
    India
  • On CPHI since:
    2015
Contact info
Show contact info Hide contact info

MSN Laboratories Resources (1)

  • MSN corporate overview

    Brochure MSN corporate overview

    MSN Group is one of the fastest-growing, research-based and fully integrated pharmaceutical companies based out of Hyderabad, India. It was founded in the year 2003 with a mission to make high-quality medicines affordable and accessible to the world. The organization presently has 24 state-of-the-art manufacturing facilities (16 API and 8 Finished Dosage Facilities) established across India and USA. The group has an integrated R&D centre that facilitates the research of both API and Finished Dosages under one roof, enabling the organization to introduce new and affordable therapies in global markets swiftly.